Status:

COMPLETED

18F-fluorocholine and 18F-fluoride PET in Prostate Cancer

Lead Sponsor:

Buddhist Tzu Chi General Hospital

Conditions:

Prostate Cancer

Fluorocholine

Eligibility:

MALE

20+ years

Phase:

NA

Brief Summary

Prostate cancer remains to be a public health problem around the world. For patients with prostate cancer, diphosphonate bone scintigraphy (BS) and pelvic tomographic imaging are major imaging tools t...

Detailed Description

The investigators conducted a prospective study to investigate the performance of 18F-choline (FCH) PET/CT and 18F-NaF PET in the patients with prostate adenocarcinoma. 18F-NaF PET imaging protocol: ...

Eligibility Criteria

Inclusion

  • Patients are pathologically diagnosed with prostate adenocarcinoma.
  • Received NaF PET/CT.

Exclusion

  • Diagnosed to have multiple cancers
  • Younger than 20-year-old
  • Known allergic to investigational drug
  • The patients is classified as not suited for the exam by the investigators.

Key Trial Info

Start Date :

February 1 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 31 2019

Estimated Enrollment :

36 Patients enrolled

Trial Details

Trial ID

NCT04340765

Start Date

February 1 2018

End Date

December 31 2019

Last Update

April 13 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Hualien Tzu Chi Hospital

Hualien City, Taiwan, 970